pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,008 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1833Endpoints1420Fierce Biotech742BioSpace733BioPharma Dive541raps241onclive165fda recalls
therapy area
allOncology12628Rare Disease3289Immunology2966Cardiology2832Hematology2240Pulmonology2207Vaccines
  • CG Oncology's bladder cancer immunotherapy cuts tumor recurrence risk by 68% in study
    CG Oncology reported that its bladder cancer immunotherapy, cretostimogene, achieved a 68% reduction in tumor recurrence compared with standard care. The treatment uses an engineered common cold v…
    STAT · 5h agoPositive readoutPositive↗ source
  • Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting rare blood cancers
    Eli Lilly announced it will acquire Calytrix Bio, a Massachusetts biotech, in a deal valued at up to $1.5 billion. Calytrix focuses on precision therapies for myeloproliferative neoplasms, includi…
    BioPharma Dive · 5h agoDealPositive↗ source
← prev
page 1 of 121
next →
116
fda medwatch112
globenewswire health73
fda press59
1821
Psychiatry & CNS1225
Ophthalmology1110
Endocrinology & Metabolism794
Pain784
Nephrology767
  • Choosing the Right AI Infrastructure Is Key to Accelerating Future Drug Discoveries
    Scientific AI is reshaping drug discovery by allowing developers to predict molecule behavior and design new compounds using models trained on protein structures, genomic data, and experimental res…
    BioPharma Dive · 8h agoNeutral↗ source
  • Clinical AI pilots stall due to organizational environment, not technology
    Clinical teams are increasingly using artificial intelligence to draft regulatory paperwork, assist data review, shape trial design and interpret complex evidence. The technology is proving its val…
    BioPharma Dive · 8h agoNeutral↗ source
  • Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with Sanofi
    Seawolf Therapeutics, a San Diego-based DNA-therapy startup, announced a $100 million financing round as it emerges from stealth. The round was led by Versant Ventures with participation from MPM…
    BioPharma Dive · 8h agoDealPositive↗ source
  • Biotech sector rebounds but gains are uneven, with Chinese firms and a large Sofinnova fund leading the surge
    Biotech companies are experiencing a strong year overall, yet investor reactions to positive clinical data remain mixed. Chinese biotech firms are emerging as the top performers, outpacing many pe…
    STAT · 1h agoDealNeutral↗ source
  • Versant and Eli Lilly commit $100 million to launch Seawolf Therapeutics, a non-viral gene-therapy startup
    Versant Ventures, Eli Lilly and other investors announced a $100 million financing round to create Seawolf Therapeutics, a new company focused on non-viral gene delivery. The startup aims to overc…
    STAT · 8h agoDealPositive↗ source
  • AAMC leadership stays vigilant after midterm shift, urges continued congressional support for research
    The Association of American Medical Colleges gathered about 4,100 educators, researchers, clinicians and trainees at its annual meeting in Anaheim, California, a short walk from Disneyland. AAMC C…
    STAT · 8h agoRegulatoryNeutral↗ source
  • Sofinnova Partners raises €725M crossover fund to back later-stage European biotech firms
    Sofinnova Partners, a leading European life‑science venture firm, announced that it has closed a second crossover fund worth 725 million euros (about $815 million). The new vehicle, called Sofinnov…
    BioPharma Dive · 11h agoDealPositive↗ source
  • CDC finds 10% of U.S. adults used GLP-1 drugs in 2025, 20% of them took compounded versions; Russia may seize foreign drug IP
    The Centers for Disease Control and Prevention reported that during July and August 2025 roughly one in ten U.S. adults said they had taken a GLP-1 medication at some point in the prior year. Amon…
    STAT · 3h agoNeutral↗ source
  • Democrats adopt "Medicare for More" as new health-care expansion message
    Democrats in the House have agreed on a new policy slogan, "Medicare for More," signaling a push to broaden health‑care coverage. The phrase is meant to set the agenda apart from the more ambitiou…
    STAT · 4h agoNeutral↗ source
  • New polymer lidding technologies aim to make pharmaceutical blister packs fully recyclable
    Pharmaceutical manufacturers are increasingly prioritizing sustainability in material selection, packaging design and end-of-life handling. The goal is to lower environmental impact while keeping p…
    BioPharma Dive · 8h agoPositive↗ source
  • BeOne Medicines and Hengrui Lead STAT-WireScreen’s China Biotech Powerhouse 25 Ranking
    STAT and risk‑intelligence platform WireScreen have published a new ranking called China’s Biotech Powerhouse 25, which lists the most valuable publicly traded biotech companies in the country. Th…
    STAT · 8h agoNeutral↗ source
  • STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
    A psychedelic drug from Helus Pharma improved depression in a study, but is facing safety questions with a number of serious adverse events reported.
    STAT · 5h agoRegulatoryNeutral↗ source
  • Physician burnout persists as hospitals push self-care instead of systemic fixes
    In a new STAT+ column, former ENT surgeon Frances Mei Hardin reflects on the growing crisis of physician burnout and the limited impact of hospital‑mandated wellness programs. Hardin shares a pers…
    STAT · 8h agoNegative↗ source
  • Apple and OpenEvidence Begin Study of Experimental AI Health Chat App
    Apple and OpenEvidence have launched a study centered on an experimental AI-powered health chat application. The pilot allows users to link personal health data to the chatbot, which then provides…
    STAT · 16h agoNeutral↗ source
  • Health-care providers turn to lawsuits over unpaid services as insurance costs squeeze paychecks
    Health-care providers are increasingly filing lawsuits to collect unpaid fees, according to a STAT+ newsletter that cites cases such as an air-ambulance company suing a plumber and a claim involvin…
    STAT · 1h agoNegative↗ source
  • VC John Doerr praises Tom Health AI tool as promising solution for primary care
    Venture capitalist John Doerr highlighted a new artificial-intelligence platform called Tom Health, noting its potential impact on primary-care delivery. Doerr, whose brother's name inspired the c…
    STAT · 7h agoPositive↗ source
  • Kennedy's MAHA Initiative Gains Momentum with Stephen Miller as White House Chief of Staff
    Stephen Miller's recent appointment as White House chief of staff has been described as a catalyst for the health secretary's MAHA agenda. The move appears to have energized the initiative, accordi…
    STAT · 8h agoPositive↗ source
  • Proposal to start medical school after Step 1 exam to cut debt and boost diversity
    The authors, bioethicists at SUNY Upstate Medical University, argue that medical education should be split into two distinct phases. The first phase would cover the pre‑clinical sciences that are t…
    STAT · 8h agoPositive↗ source
  • STAT+: NIAID acting head John Powers III appointed as the permanent director
    The acting director of NIAID, John Powers III, will become the permanent director, the agency announced Monday.
    STAT · 27m ago↗ source
  • Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
    The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.
    BioPharma Dive · 1h ago↗ source
  • CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
    CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.
    BioPharma Dive · 1h ago↗ source
  • J&J bets $2.2B on Ollin’s vision loss drug
    The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
    BioPharma Dive · 1h ago↗ source
  • STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
    The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.
    STAT · 1d ago↗ source